These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23698003)

  • 1. A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension.
    Byrd JB; Brook RD
    J Hum Hypertens; 2014 Jan; 28(1):3-9. PubMed ID: 23698003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reviving the use of aldosterone inhibitors in treating hypertension in obesity.
    Huby AC; Belin De Chantemèle EJ
    Am J Physiol Regul Integr Comp Physiol; 2015 Nov; 309(9):R1065-7. PubMed ID: 26157057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW
    Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity, sleep apnea, aldosterone, and hypertension.
    Goodfriend TL
    Curr Hypertens Rep; 2008 Jun; 10(3):222-6. PubMed ID: 18765094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells.
    Ehrhart-Bornstein M; Arakelyan K; Krug AW; Scherbaum WA; Bornstein SR
    Endocr Res; 2004 Nov; 30(4):865-70. PubMed ID: 15666838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid-induced sodium appetite and renal salt retention: evidence for common signaling and effector mechanisms.
    Fu Y; Vallon V
    Nephron Physiol; 2014; 128(1-2):8-16. PubMed ID: 25376899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipocytes, aldosterone and obesity-related hypertension.
    Dinh Cat AN; Friederich-Persson M; White A; Touyz RM
    J Mol Endocrinol; 2016 Jul; 57(1):F7-F21. PubMed ID: 27357931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of mineralocorticoid action in the brain in salt-sensitive hypertension.
    Oki K; Gomez-Sanchez EP; Gomez-Sanchez CE
    Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):90-5. PubMed ID: 21585422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6.
    Sturgis LC; Cannon JG; Schreihofer DA; Brands MW
    Am J Physiol Regul Integr Comp Physiol; 2009 Dec; 297(6):R1742-8. PubMed ID: 19812355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension and low plasma renin activity: presumptive evidence for mineralocorticoid excess.
    Spark RF; Melby JC
    Ann Intern Med; 1971 Dec; 75(6):831-6. PubMed ID: 5134893
    [No Abstract]   [Full Text] [Related]  

  • 11. The development of hypertension and hyperaldosteronism in a rodent model of life-long obesity.
    Northcott CA; Fink GD; Garver H; Haywood JR; Laimon-Thomson EL; McClain JL; Pires PW; Rainey WE; Rigsby CS; Dorrance AM
    Endocrinology; 2012 Apr; 153(4):1764-73. PubMed ID: 22355066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor activation in obesity hypertension.
    Nagase M; Fujita T
    Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension and the expanding role of aldosterone.
    Mackenzie SM; Connell J
    Curr Hypertens Rep; 2006 Jun; 8(3):255-61. PubMed ID: 17147925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone, mineralocorticoid receptors and vascular inflammation.
    Funder JW
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):263-9. PubMed ID: 15134827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there unknown mineralocorticoids in low-renin essential hypertension?
    Hollifield JW; Slaton PE; Wilson HM; Sennett JA; Yarbro L; Island DP; Liddle GW
    Mayo Clin Proc; 1977 May; 52(5):329-33. PubMed ID: 323587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of aldosterone in the pathogenesis of diabetic retinopathy.
    Liu K; Zou H; Fan H; Hu H; Cheng Y; Liu J; Wu X; Chen B; You Z
    Front Endocrinol (Lausanne); 2023; 14():1163787. PubMed ID: 37113483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid exposure and receptor activity modulate microvascular endothelial function in African Americans with and without hypertension.
    Mohandas A; Suboc TB; Wang J; Ying R; Tarima S; Dharmashankar K; Malik M; Widlansky ME
    Vasc Med; 2015 Oct; 20(5):401-8. PubMed ID: 25978968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug mechanisms to help in managing resistant hypertension in obesity.
    Jansen PM; Danser JA; Spiering W; van den Meiracker AH
    Curr Hypertens Rep; 2010 Aug; 12(4):220-5. PubMed ID: 20532698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An approach to mineralocorticoid hormone hypertension.
    Biglieri EG
    Cardiovasc Clin; 1978; 9(1):91-7. PubMed ID: 667888
    [No Abstract]   [Full Text] [Related]  

  • 20. Aldosterone sensitivity: an opportunity to explore the pathogenesis of hypertension.
    Gray Z; Tu W; Chertow GM; Bhalla V
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F325-F335. PubMed ID: 33491565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.